Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Premarin: The Intriguing History of a Controversial Drug

Author(s):  Vance Dwight A

Issue:  Jul/Aug 2007 - Hormone Replacement Therapy
View All Articles in Issue

Page(s):  282-286

Premarin: The Intriguing History of a Controversial Drug Page 1
Premarin: The Intriguing History of a Controversial Drug Page 2
Premarin: The Intriguing History of a Controversial Drug Page 3
Premarin: The Intriguing History of a Controversial Drug Page 4
Premarin: The Intriguing History of a Controversial Drug Page 5

Download in electronic PDF format for $75

Abstract:  Premarin, a complex of conjugated equine estrogens manufactured by Wyeth for use as hormone replacement therapy in women, was originally developed by the Canadian pharmaceutical firm Ayerst, McKenna and Harrison. The name Premarin was coined from pregnant mare urine, from which the estrogen complex was isolated. Although the complete composition of Premarin and its active components remains undisclosed or unknown, Wyeth reports that it contains a mixture of 10 estrogens. The history of Premarin is entangled in a fascinating story of human intrigue involving ingenuity, influence, controversy, animal rights, competition, money, protection of stockholders, government regulatory power, patient rights, emotions, greed, power, personal and professional freedom, state rights, and perhaps even, ultimately, constitutional issues. As the saga of Premarin evolves, it no doubt will continue to be one of the more interesting and compelling stories of the practice of pharmacy.

Related Keywords: Dwight A. Vance, DPh, Premarin, pregnant mare urine, conjugated equine estrogens, progestin, Prempro, hormone replacement therapy, HRT, U.S. Food and Drug Administration, FDA, regulation, regulatory

Related Categories: BUSINESS, HISTORY, HRT, LEGAL, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Premarin: The Intriguing History of a Controversial Drug
Vance Dwight A
Jul/Aug 2007
Pg. 282-286

The Science Behind Hormone Replacement Therapy, Part 1
Wepfer Scott T
Nov/Dec 2001
Pg. 462-464

Menopausal Symptom Relief and Side Effects Experienced by Women Using Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 1
Deleruyelle Laura J
Sep/Oct 2016
Pg. 359-364

Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 2
Deleruyelle Laura J
Nov/Dec 2016
Pg. 447-454

PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
Sep/Oct 2017
Pg. 356

Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 3
Deleruyelle Laura J
Jan/Feb 2017
Pg. 6-16

Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Allen Loyd V Jr
Jul/Aug 2016
Pg. 351

View Sample
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone
Brunner Scott
Jan/Feb 2023
Pg. 22-23

The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States
Stephenson Kenna
, Jones William, Stephenson Douglas M M
May/Jun 2006
Pg. 175-183

U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Miller David G
Jul/Aug 2015
Pg. 303-305

A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 1
Gillson George R
, Zava David T
Jul/Aug 2003
Pg. 250-256

U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Allen Loyd V Jr
Nov/Dec 2015
Pg. 487-488

Bioidentical Hormone Replacement Therapy, Part 3, A Review of
Wepfer Scott T
Mar/Apr 2002
Pg. 142-146

U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Yoch Doug
Mar/Apr 2017
Pg. 95-102

Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Brunner Scott
Jul/Aug 2020
Pg. 296-297

U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line
Snow Stephen T
, Stannard Robert W, Bellis Jennifer, Moss Carrie A
Jan/Feb 2019
Pg. 32-33

The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter
Miller David G
May/Jun 2014
Pg. 208

Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens - Part 2
Ford Gina
, Garcia Lea
Jan/Feb 2001
Pg. 52-54

Hormone Replacement Therapy, Part 2: Estrogen Defined
Lorentzen Jean
Nov/Dec 2001
Pg. 460-461

Hormone Replacement Therapy: Part 1 - The Evolution of Hormone Treatment
Lorentzen Jean
Sep/Oct 2001
Pg. 336-338

Return to Top